← All research updates

Tiny immune cell packets slowed brain tumors in mice

Original title: Natural Killer Cell-Derived Extracellular Vesicle Preparations Demonstrate Potent Antitumor Activity Against Human Glioblastoma In Vitro and In Vivo.

How far along is this research?

This was done in animals, not people. Most findings at this stage never become treatments.

This was only done in lab dishes and in mice.

The short version

Tiny packets made by immune cells killed brain tumor cells in the lab and helped mice live longer.

What was studied. Scientists collected tiny packets released by human immune cells called natural killer cells. They tested these packets on glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary cells in dishes and in mice with glioblastoma tumors.

What they found. The packets killed several kinds of glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary cells. Bigger doses killed more cells. They even killed cells that resist normal natural killer cell treatment. In mice, the packets slowed tumor growth. Mice given the packets in a vein lived longer.

What this means, and what it doesn't

What it could mean: This points to a possible future treatment that uses cell parts instead of whole living cells. It may get around some problems that hold back immune cell therapy. For now it is a lab and animal idea, not care you can ask for.

What it doesn't mean: This does not mean a new treatment is coming soon. The work was done in dishes and in mice, not in people. No person has been treated with this. It is not proof it is safe or works in humans. It is not a cure.

Source: PubMed, September 24, 2026 · Read the original

This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.

Report a problem with this summary